1,934 reports of this reaction
10.2% of all POLATUZUMAB VEDOTIN reports
#1 most reported adverse reaction
DISEASE PROGRESSION is the #1 most commonly reported adverse reaction for POLATUZUMAB VEDOTIN, manufactured by Genentech, Inc.. There are 1,934 FDA adverse event reports linking POLATUZUMAB VEDOTIN to DISEASE PROGRESSION. This represents approximately 10.2% of all 19,009 adverse event reports for this drug.
Patients taking POLATUZUMAB VEDOTIN who experience disease progression should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DISEASE PROGRESSION is a frequently reported adverse event for POLATUZUMAB VEDOTIN, accounting for a significant proportion of all reports.
In addition to disease progression, the following adverse reactions have been reported for POLATUZUMAB VEDOTIN:
The following drugs have also been linked to disease progression in FDA adverse event reports:
DISEASE PROGRESSION has been reported as an adverse event in 1,934 FDA reports for POLATUZUMAB VEDOTIN. This does not prove causation, but indicates an association observed in post-market surveillance data.
DISEASE PROGRESSION accounts for approximately 10.2% of all adverse event reports for POLATUZUMAB VEDOTIN, making it one of the most commonly reported side effect.
If you experience disease progression while taking POLATUZUMAB VEDOTIN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.